Nantahala Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Nantahala Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$38.3M	Sell	300,000 -100,000	-25%	-$12.5M	1.41%	16
2025 Q4	$48.8M	Sell	400,000 -300,000	-43%	-$34.4M	1.61%	11
2025 Q3	$70.1M	Sell	700,000 -100,000	-13%	-$9.01M	2.44%	4
2025 Q2	$66.3M	Sell	800,000 -400,000	-33%	-$31.9M	2.6%	5
2025 Q1	$97.3M	Sell	1,200,000 -50,000	-4%	-$4.47M	3.87%	5
2024 Q4	$113M	Buy	1,250,000 +450,000	+56%	+$43.6M	4.83%	4
2024 Q3	$79M	Sell	800,000 -400,000	-33%	-$39.3M	4%	5
2024 Q2	$111M	Sell	1,200,000 -700,000	-37%	-$62.8M	6.5%	5
2024 Q1	$180M	Sell	1,900,000 -1,414,400	-43%	-$131M	10.3%	2
2023 Q4	$296M	Buy	3,314,400 +2,364,400	+249%	+$176M	17.69%	1
2023 Q3	$69.4M	Buy	+950,000	New	+$75.9M	5.93%	3
2022 Q2	–	Sell	-250,000	Closed	-$22.5M	–	134
2022 Q1	$22.5M	Sell	250,000 -400,000	-62%	-$36.9M	0.99%	28
2021 Q4	$72.8M	Buy	650,000 +150,000	+30%	+$18.1M	2.56%	6
2021 Q3	$62.9M	Buy	500,000 +100,000	+25%	+$12.9M	1.98%	11
2021 Q2	$54.2M	Buy	+400,000	New	+$52.6M	1.54%	16
2020 Q1	–	Sell	-2,250,000	Closed	-$214M	–	110
2019 Q4	$214M	Buy	2,250,000 +1,350,000	+150%	+$117M	6.59%	2
2019 Q3	$68.6M	Sell	900,000 -216,500	-19%	-$18M	2.54%	12
2019 Q2	$97.9M	Sell	1,116,500 -633,500	-36%	-$54M	3.02%	10
2019 Q1	$158M	Buy	1,750,000 +750,000	+75%	+$63.8M	4.94%	2
2018 Q4	$71.8M	Hold	1,000,000	–	–	2.21%	10
2018 Q3	$95.9M	Buy	1,000,000 +450,000	+82%	+$43.6M	2.58%	8
2018 Q2	$52.4M	Buy	550,000 +350,000	+175%	+$32.2M	2.12%	14
2018 Q1	$17.5M	Sell	200,000 -648,100	-76%	-$59.2M	0.79%	35
2017 Q4	$72M	Buy	+848,100	New	+$71M	3.2%	9
2014 Q3	–	Sell	-150,000	Closed	-$7.7M	–	107
2014 Q2	$7.7M	Buy	+150,000	New	+$6.76M	1.13%	29

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Nantahala Capital Management's XBI Position: Q4 2024 in Review

Nantahala Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 21,646 shares — an estimated $2.1M sold.

Nantahala Capital Management first reported a position in XBI in Q1 2024 and held it in 3 quarters. The position peaked at $3.99M in Q1 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

Nantahala Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
Nantahala Capital Management sold 21,646 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $2.1M.
Nantahala Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and held it in 3 quarters.
Nantahala Capital Management's State Street SPDR S&P Biotech ETF position peaked at $3.99M in Q1 2024.
738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Nantahala Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.